永泰生物-B(6978.HK)漲超8%創歷史新高 市值逼近百億
格隆匯4月22日丨永泰生物-B(6978.HK)今日盤中大肆拉昇,一度漲8.35%至18.94港元,創歷史新高,市值逼近百億港元;該股年內累漲幅度高達67%。公司是中國領先的細胞免疫治療領域的18A生物製藥企業,共有十餘種在研產品,覆蓋的適應症不僅有傳統細胞治療作用的血液瘤領域。今年2月,公司公吿了CAR-T細胞產品系列中的第一個在研產品CAR-T-19,舉行臨牀一期啟動會。根據與會機構及專家討論確定,永泰生物CAR-T-19一期臨牀試驗,預計於2021年5月啟動病例入組工作,2022年第一季度入組完成全部計劃的病例,2022年年內出具統計分析及總結報吿。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.